Prognostic and predictive value of epigenetic silencing of MGMT in patients with high grade gliomas: a systematic review and meta-analysis

O6-Methylguanine-DNA methyltransferase protein expression by immunohistochemistry in brain and non-brain systemic tumours: systematic review and meta-analysis of correlation with methylation-specific polymerase chain reaction

(2011) Marta Brell et al.   BMC CANCER

MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma

(2011) A. L. Rivera et al.   NEURO-ONCOLOGY

Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy

(2009) J Dunn et al.   BRITISH JOURNAL OF CANCER

Prognostic impact of O6-methylguanine-DNA methyltransferase silencing in patients with recurrent glioblastoma multiforme who undergo surgery and carmustine wafer implantation

(2009) Philippe Metellus et al.   CANCER

Prognostic Significance of Molecular Markers and Extent of Resection in Primary Glioblastoma Patients

(2009) J. Felsberg et al.   CLINICAL CANCER RESEARCH

Long-Term Survival of Patients With Glioblastoma Treated With Radiotherapy and Lomustine Plus Temozolomide

(2009) Martin Glas et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase II Trial of Chemoradiotherapy Followed by Either Dose-Dense or Metronomic Temozolomide for Newly Diagnosed Glioblastoma

(2009) Jennifer L. Clarke et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Trial of Temozolomide Plus O6-Benzylguanine in Adults With Recurrent, Temozolomide-Resistant Malignant Glioma

(2009) Jennifer A. Quinn et al.   JOURNAL OF CLINICAL ONCOLOGY

Molecular Predictors of Progression-Free and Overall Survival in Patients With Newly Diagnosed Glioblastoma: A Prospective Translational Study of the German Glioma Network

(2009) Michael Weller et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic value of O6-methylguanine-DNA methyltransferase status in glioblastoma patients, assessed by five different methods

(2009) Lucie Karayan-Tapon et al.   JOURNAL OF NEURO-ONCOLOGY

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

(2009) Roger Stupp et al.   LANCET ONCOLOGY

MGMT METHYLATION IS A PROGNOSTIC BIOMARKER IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA

(2009) E. R. Gerstner et al.   NEUROLOGY

Methylation status of the MGMT gene promoter fails to predict the clinical outcome of glioblastoma patients treated with ACNU plus cisplatin

(2009) Chul-Kee Park et al.   NEUROPATHOLOGY

A MDR1 (ABCB1) gene single nucleotide polymorphism predicts outcome of temozolomide treatment in glioblastoma patients

(2008) M. Schaich et al.   ANNALS OF ONCOLOGY

MGMTPromoter Methylation Status Can Predict the Incidence and Outcome of Pseudoprogression After Concomitant Radiochemotherapy in Newly Diagnosed Glioblastoma Patients

(2008) Alba A. Brandes et al.   JOURNAL OF CLINICAL ONCOLOGY

Promoter Methylation and Polymorphisms of the MGMT Gene in Glioblastomas: A Population-Based Study

(2008) Izabela Zawlik et al.   NEUROEPIDEMIOLOGY

Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3

(2007) Thierry Gorlia et al.   LANCET ONCOLOGY